EphB4 forward signalling regulates lymphatic valve development

Nature Communications

Volumn 6, Issue , 2015, Pages

  Zhang, Gu ^a   Brady, John ^a   Liang, Wei Ching ^a   Wu, Yan ^a   Henkemeyer, Mark ^b   Yan, Minhong ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B4; IMMUNOGLOBULIN F(AB) FRAGMENT; EFNB2 PROTEIN, MOUSE; EPHB4 PROTEIN, MOUSE; EPHRIN B2; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; PHOSPHOTRANSFERASE;

ANTIBODY; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITION; MUTATION; RODENT; SIGNALING;

3T3 CELL LINE; ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LYMPH FLOW; LYMPHANGIOGENESIS; LYMPHATIC VALVE DEVELOPMENT; NEWBORN; NONHUMAN; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL; AMINO ACID SEQUENCE; ANATOMY AND HISTOLOGY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; LYMPH VESSEL; METABOLISM; MOLECULAR GENETICS; MORPHOGENESIS; MOUSE; PEPTIDE LIBRARY; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION;

MUS;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; EPHRIN-B2; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHATIC VESSELS; MICE; MOLECULAR SEQUENCE DATA; MORPHOGENESIS; NIH 3T3 CELLS; PEPTIDE LIBRARY; PHOSPHOTRANSFERASES; PROTEIN ENGINEERING; RECEPTOR, EPHB4; SIGNAL TRANSDUCTION;

EID: 84927947282     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7625     Document Type: Article

References (35)

1. Alitalo, K., Tammela, T. & Petrova, T. V. Lymphangiogenesis in development and human disease. Nature 438, 946-953 (2005).
2. Choi, I., Lee, S. & Hong, Y. K. The new era of the lymphatic system: no longer secondary to the blood vascular system. Cold Spring Harb. Perspect. Med. 2, a006445 (2012).
3. Bazigou, E. & Makinen, T. Flow control in our vessels: vascular valves make sure there is no way back. Cell. Mol. Life. Sci. 70, 1055-1066 (2012).
4. Bazigou, E. et al. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev. Cell 17, 175-186 (2009).
5. Bouvree, K. et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circ. Res. 111, 437-445 (2012).
6. Jurisic, G. et al. An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation. Circ. Res. 111, 426-436 (2012).
7. Kanady, J. D., Dellinger, M. T., Munger, S. J., Witte, M. H. & Simon, A. M. Connexin37 and Connexin43 deficiencies in mice disrupt lymphatic valve development and result in lymphatic disorders including lymphedema and chylothorax. Dev. Biol. 354, 253-266 (2011).
8. Levet, S. et al. Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation. Blood 122, 598-607 (2013).
9. Makinen, T. et al. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 19, 397-410 (2005).
10. Petrova, T. V. et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nature Med. 10, 974-981 (2004).
11. Sabine, A. et al. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev. Cell 22, 430-445 (2012).
12. Pasquale, E. B. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell. Biol. 6, 462-475 (2005).
13. Pitulescu, M. E. & Adams, R. H. Eph/ephrin molecules - a hub for signaling and endocytosis. Genes Dev. 24, 2480-2492 (2010).
14. Wang, H. U., Chen, Z. F. & Anderson, D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93, 741-753 (1998).
15. Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487-491 (2010).
16. Davy, A. & Soriano, P. Ephrin signaling in vivo: look both ways. Dev. Dyn. 232, 1-10 (2005).
17. Armstrong, J. N. et al. B-ephrin reverse signaling is required for NMDA-independent long-term potentiation of mossy fibers in the hippocampus. J. Neurosci. 26, 3474-3481 (2006).
18. Bouzioukh, F. et al. Tyrosine phosphorylation sites in ephrinB2 are required for hippocampal long-term potentiation but not long-term depression. J. Neurosci. 27, 11279-11288 (2007).
19. Bush, J. O. & Soriano, P. Ephrin-B1 regulates axon guidance by reverse signaling through a PDZ-dependent mechanism. Genes Dev. 23, 1586-1599 (2009).
20. Dravis, C. et al. Bidirectional signaling mediated by ephrin-B2 and EphB2 controls urorectal development. Dev. Biol. 271, 272-290 (2004).
21. Xu, N. J. & Henkemeyer, M. Ephrin-B3 reverse signaling through Grb4 and cytoskeletal regulators mediates axon pruning. Nat. Neurosci. 12, 268-276 (2009).
22. Xu, N. J., Sun, S., Gibson, J. R. & Henkemeyer, M. A dual shaping mechanism for postsynaptic ephrin-B3 as a receptor that sculpts dendrites and synapses. Nat. Neurosci. 14, 1421-1429 (2011).
23. Bazigou, E. et al. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J. Clin. Invest. 121, 2984-2992 (2011).
24. Adams, R. H. et al. Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev. 13, 295-306 (1999).
25. Gerety, S. S., Wang, H. U., Chen, Z. F. & Anderson, D. J. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol. Cell 4, 403-414 (1999).
26. Thakar, S., Chenaux, G. & Henkemeyer, M. Critical roles for EphB and ephrin-B bidirectional signalling in retinocollicular mapping. Nat. Commun. 2, 431 (2011).
27. Jorgensen, C. et al. Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-1509 (2009).
28. Cowan, C. A. et al. Ephrin-B2 reverse signaling is required for axon pathfinding and cardiac valve formation but not early vascular development. Dev. Biol. 271, 263-271 (2004).
29. Dravis, C. & Henkemeyer, M. Ephrin-B reverse signaling controls septation events at the embryonic midline through separate tyrosine phosphorylation-independent signaling avenues. Dev. Biol. 355, 138-151 (2011).
30. Martiny-Baron, G. et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis 13, 259-267 (2010).
31. Gallion, S. L. & Qian, D. Chemical genetic approaches to kinase drug discovery. Curr. Opin. Drug. Discov. Devel. 8, 638-645 (2005).
32. Williams, R. & Brown, K. Chemical genetics and genomics and drug discovery. Highlights from the Society for Medicines Research symposium held Thursday March 10, 2005, in London, United Kingdom. Drug News Perspect. 18, 285-288 (2005).
33. Katsuta, H. et al. EphrinB2-EphB4 signals regulate formation and maintenance of funnel-shaped valves in corneal lymphatic capillaries. Invest. Ophthalmol. Vis. Sci. 54, 4102-4108 (2013).
34. Lee, C. V. et al. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. 340, 1073-1093 (2004).
35. Liang, W. C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).